, /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: ), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it will host a conference call on at / to discuss topline data from the Company's Phase CARPO trial of AuxoraTM in acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS). Stockholders and other interested parties may participate in the call by following the instructions below.
A live webcast of the event can also be accessed in the "Upcoming Events" section of CalciMedica's IR website at . A replay of the webcast will be available following the completion of the event. 1-800-836-8184 (US) and 1-646-357-8785 (international) CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases.
CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate AuxoraTM has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has complete.
